Neurimmune Holding AG:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Neurimmune Holding AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7580
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Neurimmune Holding AG (Neurimmune), formerly Neurimmune Therapeutics AG is a biopharmaceutical company that develops immunotherapeutics for human diseases. The company’s pipeline products include human-derived monoclonal antibodies developed for the treatment and prevention of human neurodegenerative disorders through preclinical development. It develops reverse translational medicine technology platform which creates recombinant human-derived monoclonal antibodies as therapeutics. Neurimmune’s human-derived monoclonal antibodies are used as drug candidates in the treatment of diseases such as Alzheimer’s disease, Parkinson’s disease, central nervous system disorders, transthyretin amyloidosis, type-2 diabetes, tauopathies and amyotrophic lateral sclerosis. The company also conducts research and development programs on progressive multifocal leukoencephalopathy, neuropathy, Huntington’s disease and cardiomyopathy. Neurimmune is headquartered in Zurich, Switzerland.

Neurimmune Holding AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neurimmune Holding AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
AL-S Pharma Secures Investment from Neurimmune and TVM Capital Life Science Venture Capital 10
Partnerships 11
Biogen Exercises Option Agreement with Neurimmune 11
Neurimmune Therapeutics Enters into Co-Development Agreement with Ono Pharma 12
Ramot at Tel Aviv University Enters into Research Agreement with Neurimmune 13
ALS TDI and Anelixis Therapeutics Enters into Research Agreement with Neurimmune 14
Licensing Agreements 15
Mabimmune Enters into Collaborative Research Agreement with Neurimmune 15
Neurimmune Holding AG – Key Competitors 16
Neurimmune Holding AG – Key Employees 17
Neurimmune Holding AG – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Corporate Communications 19
Sep 12, 2018: Neurimmune names Christoph Hock as Chief Medical Officer to lead clinical development 19
Apr 26, 2018: Neurimmune appoints Fabian Buller as Chief Business Officer 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Key Facts 2
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neurimmune Holding AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neurimmune Holding AG, Deals By Therapy Area, 2012 to YTD 2018 8
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
AL-S Pharma Secures Investment from Neurimmune and TVM Capital Life Science Venture Capital 10
Biogen Exercises Option Agreement with Neurimmune 11
Neurimmune Therapeutics Enters into Co-Development Agreement with Ono Pharma 12
Ramot at Tel Aviv University Enters into Research Agreement with Neurimmune 13
ALS TDI and Anelixis Therapeutics Enters into Research Agreement with Neurimmune 14
Mabimmune Enters into Collaborative Research Agreement with Neurimmune 15
Neurimmune Holding AG, Key Competitors 16
Neurimmune Holding AG, Key Employees 17

List of Figures
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Neurimmune Holding AG:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Advaxis Inc (ADXS):企業の財務・戦略的SWOT分析
    Advaxis Inc (ADXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Gilead Sciences Inc (GILD)-医療機器分野:企業M&A・提携分析
    Summary Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) in …
  • CSL Limited:企業のM&A・事業提携・投資動向
    CSL Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CSL Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Bechtel Corporation:企業の戦略的SWOT分析
    Bechtel Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Toyo Tanso Co Ltd (5310):企業の財務・戦略的SWOT分析
    Toyo Tanso Co Ltd (5310) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Enerjisa Enerji Uretim AS:電力:M&Aディール及び事業提携情報
    Summary Enerjisa Enerji Uretim A.S. (Enerjisa Enerji), a subsidiary of Enerjisa Enerji A.S, is an energy utility. The company generates electricity from natural gas, lignite coal, hydro, and wind sources. It owns and operates wind plants such as Canakkale in Mahmudiye, Dagpazari in Mut, and Balikesi …
  • Azul SA (AZUL):企業の財務・戦略的SWOT分析
    Azul SA (AZUL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Falco SD Holdings Co Ltd (4671):企業の財務・戦略的SWOT分析
    Summary Falco SD Holdings Co Ltd (Falco), formerly Falco Biosystems Ltd is a clinical testing and dispensing pharmacy service provider. The company offers services such as genetic testing, clinical trials, medical information systems development, and food sanitation and environmental testing. It pro …
  • The British United Provident Association Limited:企業の戦略・SWOT・財務分析
    The British United Provident Association Limited - Strategy, SWOT and Corporate Finance Report Summary The British United Provident Association Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, …
  • OraSolv AB (OS):企業の財務・戦略的SWOT分析
    OraSolv AB (OS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Ennis, Inc. (EBF):企業の財務・戦略的SWOT分析
    Ennis, Inc. (EBF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • New Britain Palm Oil Limited:企業の戦略・SWOT・財務情報
    New Britain Palm Oil Limited - Strategy, SWOT and Corporate Finance Report Summary New Britain Palm Oil Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Aptiv Plc:企業の戦略・SWOT・財務分析
    Aptiv Plc - Strategy, SWOT and Corporate Finance Report Summary Aptiv Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Novozymes AS (NZYM B):製薬・医療:M&Aディール及び事業提携情報
    Summary Novozymes AS (Novozymes) is a biotech company that produces, markets and sells a range of industrial enzymes and microorganisms. The company provides enzymes for detergents, technical, food and feed industries. It supplies a range of microorganisms for use in agriculture, industrial cleaning …
  • Olympia Vodice d.d.:企業の戦略・SWOT・財務情報
    Olympia Vodice d.d. - Strategy, SWOT and Corporate Finance Report Summary Olympia Vodice d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • James Fisher and Sons Plc (FSJ):電力:M&Aディール及び事業提携情報
    Summary James Fisher and Sons Plc (James Fisher) is a service provider for global marine industry and a specialist supplier of engineering services to the energy industry. The company provides comprehensive services such as design and engineering; inspection and monitoring; lifting and handling; mar …
  • Rizzani De Eccher S.P.A.
    Rizzani De Eccher S.P.A. - Strategy, SWOT and Corporate Finance Report Summary Rizzani De Eccher S.P.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Bharat Heavy Electricals Ltd (BHEL):電力:M&Aディール及び事業提携情報
    Summary Bharat Heavy Electricals Limited (BHEL) is an integrated power plant equipment manufacturer that designs, manufactures, constructs, tests, commissions and services a broad range of products. Its product portfolio includes transformers, valves and oil field equipment, electrostatic precipitat …
  • Trianni Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Trianni Inc (Trianni) is a developer of fully human monoclonal antibodies that provides its propriety discovery platform. The company provides Trianni Mouse platform that holds engineered versions of three antibody-encoding genetic loci, namely, Heavy, Kappa, Lambda, and others. It enables t …
  • Lantheus Medical Imaging Inc:医療機器:M&Aディール及び事業提携情報
    Summary Lantheus Medical Imaging Inc (Lantheus Medical), a subsidiary of Lantheus Holdings, Inc., develops, manufactures, and commercializes diagnostic imaging agents and products for the diagnosis of conditions that affect heart, brain, lungs and other organs using echocardiography and nuclear imag …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆